top of page

Zevra Therapeutics Media Release | April 15, 2024

Zevra Therapeutics Presents New Data On The Long-Term Safety And Efficacy Of Arimoclomol As A Treatment For Niemann-Pick Disease Type C At The SIMD 45th Annual Meeting

Read the full statement from Zevra Therapeutics here:

Here is a summary of the article:


To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."

Ways to support NP-C in Australia:

28 views0 comments


Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page